Clinical trial · Observational
Prognostic Value of Protein IMP3 Expression in Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The results of recent research on cervical cancer and its precancerous lesions have linked the expression of IMP3 protein to cervical dysplasia and the possibility of severe cervical dysplasia (CIN III) progressing to squamous cell carcinoma. A higher expression of IMP3 protein was found in the cytoplasms of severe cervical dysplasia (CIN III) cells and invasive tumor cells compared to CIN I and CIN II change cells. The sensitivity of IMP3 expression in tumor cells was 96%. In preparations that were IMP3 negative, no further monitoring and treatment revealed squamous cell carcinoma. Further analyzes indicated the possibility of determining IMP3 expression on first cervical biopsy specimens in patients with HSIL ( high grade squamous intraepithelial lesion) lesions as a biomarker to detect a subset of patients in whom lesion invasiveness can be expected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Carcinoma | Cervical Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- FIGO group 1A1
- description
- 20 subjects with tumor invasion depth up to 1 mm
- interventionNames
- Other: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
- label
- FIGO group 1A2
- description
- 20 subjects with an invasion depth of 1 - 3 mm
- interventionNames
- Other: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
- label
- FIGO group 1B1
- description
- 20 subjects with invasion depth up to 2 cm
- interventionNames
- Other: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * operated women diagnosed with squamous cell carcinoma of the cervix at the figo stage 1a1, 1a2, 1b1 and 1b2 Exclusion Criteria: * patients who underwent preoperative chemo and / or radiotherapy * patients with associated gynecological or other malignant diseases * patients with other histological types of tumors (adenocarcinoma, adenosquamous, neuroendocrine, etc.)
References
Publications (0)
Data not yet available